15 September 2014
Breda, the Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today that it has appointed Petercam NV as a liquidity provider for the Company's common shares currently listed on Euronext Brussels under the trading symbol ARGX.
A liquidity provider facilitates the buying and selling of shares in order to narrow the difference between the bid and ask prices of a traded security. The liquidity provider's goal is to improve the marketability of the shares, enabling shareholders to more efficiently trade in the Company's common stock so that in normal circumstances adequate liquidity can be maintained. The agreement between Petercam NV and the Company is compliant with Euronext Rule Book for liquidity providers. The agreement is effective as of 18 September 2014.
###
About Petercam NV
Petercam is a leading independent investment firm specializing in private banking, institutional asset management and investment banking (corporate finance and financial intermediation).
As a financial advisor, it offers the highest standards in the execution of corporate financing projects. The services range from M&A, capital market transactions and fairness opinions, both in Belgium and internationally thanks to the exclusive M&A alliance with houses in more than 40 countries.
Thanks to its expertise in research based equity brokerage, Petercam has developed long lasting relationships with institutional clients and is respected for its placement power. Drawing on a team of analysts, sales and traders based in Brussels, Amsterdam and New York, it acts as a leading broker in Benelux stocks and institutional bonds.
As at 31 December 2013, Petercam employed 421 people and managed assets totaling approximately 14 billion euro for private and institutional clients, corporates and public institutions.
About arGEN-X
arGEN-X is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. arGEN-X has generated a pipeline of differentiated clinical and preclinical antibody candidates using its SIMPLE Antibody(TM) discovery platform. SIMPLE Antibody(TM) has a particular strength in addressing novel, complex disease targets that are difficult to access using established antibody technology platforms. Proprietary Fc engineering technologies (NHance® and ABDEG(TM)) and POTELLIGENT® technology (licensed from BioWa, inc.) further enhance the therapeutic properties of SIMPLE Antibody(TM) leads in terms of tissue penetration/residence time in the body, ability to clear disease targets or pathogenic antibodies and cell-killing potency through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged its suite of antibody technologies in forging strategic collaborations with pharmaceutical and biotechnology companies to provide new approaches to diseases with unmet medical needs.
arGEN-X is listed on the Euronext Brussels exchange under the symbol ARGX.
SIMPLE Antibody(TM), NHance® and ABDEG(TM) are trademarks of arGEN-X NV
POTELLIGENT® is a trademark of BioWa Inc.
For further information, please contact:
Tim Van Hauwermeiren, Chief Executive Officer
Eric Castaldi, Chief Financial Officer
+32 (0)9 243 40 70
info@arGEN-X.com
Mark Swallow/David Dible
Citigate Dewe Rogerson
+44 207 282 2948
arGEN-X@citigatedr.co.uk
Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements arGEN-X makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. arGEN-X' actual results may differ materially from those predicted by the forward-looking statements. arGEN-X undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.